We develop cutting-edge plasmid-based reverse genetics systems and use them to manufacture high-fidelity virus stocks, reporter viruses, viral genomic material, custom mutants, and other custom virus solutions for vaccine development, antiviral research, diagnostics, and academic research.

Reverse genetics allows us to engineer viruses from genetic sequences using plasmid-based systems, providing precise control over viral characteristics for research applications. We specialize in de novo production of new virus strains and can create any virus needed, including difficult-to-grow strains.

Our clients include biotechnology companies developing vaccines and antivirals, pharmaceutical manufacturers conducting drug discovery, diagnostic companies developing and testing assays, and academic and government research institutions performing basic virology research.

All virus stocks include best-in-class QC standards: titer confirmation, next-generation sequencing verification, sterility testing, and endotoxin analysis. We also provide tailored purification and QC solutions based on specific project needs.

We work with alphaviruses, flaviviruses, coronaviruses, influenza, respiratory syncytial virus, parainfluenza viruses, human metapneumovirus, norovirus, rotavirus, measles virus, and custom viruses. We can also create reporter protein-expressing versions of any strain.

Custom projects typically require multiple weeks depending on complexity and specifications. We offer large-scale production capabilities up to 50L per production run and can provide volume expansion from seed stocks.